Press releases
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
-
Nov 12, 2020
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced today it has acquired the Medical Business assets of CUBEX LLC, which is a privately-held...
-
Nov 10, 2020
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced its rapid, point-of-care, SARS-CoV-2 antigen test for use on the BD Veritor™ Plus...
-
Nov 9, 2020
BD (Becton, Dickinson and Company) (NYSE:BDX), a leading global medical technology company, announced today that it will present at the following upcoming virtual healthcare conferences: Stifel...
-
Nov 9, 2020
FRANKLIN LAKES, N.J., Nov. 6, 2020 – BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the appointment of Paddy O’Brien to worldwide...
-
Nov 9, 2020
FRANKLIN LAKES, N.J., Nov. 6, 2020 – BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the expanded role of Tony Ezell as president of...
-
Nov 5, 2020- Fiscal fourth quarter revenues of $4.784 billion grew 4.4% on a reported and currency-neutral basis.
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today reported quarterly revenues of $4.784 billion for the fourth fiscal quarter ended September 30,...
-
Nov 2, 2020The first shipment of 1.2 million SARS-CoV-2 Assays for use on the BD Veritor™ Plus System to be delivered in The Netherlands by mid-November
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the receipt of an order from the Dutch Ministry of Health for 9.2 million of its rapid,...
-
Oct 22, 2020Patrick Kaltenbach appointed chief technology officer
Dave Hickey promoted to president, Life Sciences segmentBD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the appointment of Patrick Kaltenbach as executive vice president and chief technology...
-
Oct 21, 2020
CerTest Biotec, along with BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that the VIASURE SARS-CoV-2 (N1 + N2) Real Time PCR...
-
Oct 16, 2020BD Multitest™ 6-Color TBNK Reagent with BD Trucount™ Tubes brings time-tested immune assessment solution to European clinicians treating COVID-19 patients
EYSINS, Switzerland, Oct. 16, 2020 – BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the CE mark and European availability of a...
-
Oct 7, 2020Global Mercy will deliver free, world-class surgical care to patients in African nations who lack healthcare access
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, this year celebrates its 25 year of philanthropic partnership with the global nonprofit, Mercy Ships,...
-
Oct 6, 2020Four of every ten women received inappropriate treatment
FRANKLIN LAKES, N.J., October 6, 2020 – BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced the publication of an investigator-initiated study...
-
Oct 5, 2020BD FACSDuet™ Sample Preparation System, now available in the U.S., as the first fully automated sample-to-answer solution when integrated with the BD FACSLyric™ Flow Cytometer
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for...
-
Oct 2, 2020
BD (Becton, Dickinson and Company) (NYSE:BDX) announced today that it will conduct a live webcast of its fourth fiscal quarter and full fiscal year 2020 earnings conference call on Thursday,...
-
Sep 30, 2020SARS-CoV-2 Assay for BD Veritor™ Plus System to be available in Europe by end of October
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced its rapid, point-of-care, SARS-CoV-2 antigen test for use on the BD Veritor™ Plus...
-
Sep 24, 2020
FRANKLIN LAKES, N.J. (Sept. 24, 2020) – BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today issued the following statement: Today, the Attorneys...
-
Sep 23, 2020
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that it has submitted a pre-market approval (PMA) supplement to the U.S. Food and Drug...
-
Sep 21, 2020Three Recalls Designated as Class I by FDA; One Designated as Class II
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today provided an update on previously announced voluntary recalls of the BD Alaris™ System. Three of...
-
Sep 15, 2020
FRANKLIN LAKES, N.J. (Sept. 15, 2020) – BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today issued the following statement: BD is aware that a...
-
Sep 9, 2020Results show clinical study design may influence performance estimates and published sensitivity claims of SARS-CoV-2 antigen tests
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the results of a new research study that demonstrated performance of the BD Veritor™...
-
Aug 31, 2020
BD (Becton, Dickinson and Company) (NYSE:BDX), a leading global medical technology company, announced today that it will present at the following upcoming virtual investor healthcare conferences:...
-
Aug 24, 2020
FRANKLIN LAKES, N.J., Aug. 24, 2020 – BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the appointment of Eric Borin to worldwide...
-
Aug 20, 2020Majority of June 30 Recall Designated as Class I Recall by FDA
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today provided an update on a previously announced voluntary recall of the BD Alaris™ System. Three...
-
Aug 17, 2020
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced today the appointment of Kristen Stewart to the newly created position of senior vice...
-
Aug 13, 2020
BD (Becton, Dickinson and Company) (NYSE:BDX), a leading global medical technology company, announced today that it will present at the UBS Genomics 2.0 and MedTech Innovations Virtual Summit on...
-
Aug 10, 2020
BD (NYSE: BDX), a leading global medical technology company, together with the BD Foundation, its charitable affiliate, today committed $7.8 million in monetary grants and product donations over...
-
Aug 7, 2020
BD (Becton, Dickinson and Company), a leading global medical technology company, announced a voluntary recall on June 23, 2020 for specified catalog numbers of the ChloraPrep™ 3 mL applicator...
-
Aug 6, 2020- As reported, revenues of $3.855 billion decreased 11.4 percent
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today reported quarterly revenues of $3.855 billion for the third fiscal quarter ended June 30, 2020....
-
Aug 3, 2020
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today issued its 2019 Sustainability Report, focusing on performance of the environmental, social and...
-
Jul 30, 2020Capital investments will enable U.S. manufacturing of 8 million BD Veritor™ brand SARS-CoV-2 tests per month
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced a $24 million investment from the U.S. Department of Defense in collaboration with the...
-
Jul 28, 2020BD Kiestra™ InoqulA system is available in Europe (CE marked)
FRANKLIN LAKES, N.J., July 28, 2020 – BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced availability in Europe (CE marked) of the new...
-
Jul 27, 2020
The Board of Directors of BD (Becton, Dickinson and Company) (NYSE: BDX) has declared a quarterly dividend of $0.79 per common share, payable on September 30, 2020 to holders of record on...
-
Jul 22, 2020BD Onclarity™ HPV Assay is the only FDA-approved HPV assay to individually identify and report genotypes beyond 16, 18 and 45
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that it received approval for a pre-market approval (PMA) supplement from the U.S. Food...
-
Jul 21, 2020U.S. Orders 140 Million Additional Devices; Canada Orders 37 Million Additional Devices
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced additional pandemic orders for needles and syringes from the United States and Canada...
-
Jul 17, 2020
WARWICK, R.I. (July 17, 2020) – BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the appointment of Kevin Kelly to worldwide...
-
Jul 15, 2020Government committed to use of BD Veritor™ Plus System and 15-minute SARS-CoV-2 test kits
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced today a commitment from the U.S. Department of Health and Human Services (HHS) to purchase BD...
-
Jul 8, 2020Company Finalizes Initial Pandemic Order for 50 Million Injection Devices to Support Operation Warp Speed Vaccination Program
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the formation of a strategic, public-private partnership with the Biomedical Advanced...
-
Jul 7, 2020New BD PurPrep™ skin preparation is the only commercially available PVP-I antiseptic skin preparation with sterile solution in the U.S.
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the availability of BD PurPrep™ patient preoperative skin preparation with sterile...
-
Jul 6, 2020- Simple new assay leverages more than 25,000 BD Veritor™ instruments already used across the U.S. to immediately increase access to COVID-19 testing in frontline health care settings
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that the U.S. Food and Drug Administration (FDA) granted Emergency Use Authorization...
-
Jul 3, 2020
CME America, a wholly owned subsidiary of BD (Becton, Dickinson and Company), announced a voluntary recall for all CME America BodyGuard® Infusion System Administration Sets (infusion...
-
Jul 3, 2020First Shipments of Injection Devices Already Arrived in U.K.
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the receipt of a large pandemic order from the U.K. government for 65 million needles...
-
Jul 2, 2020
BD (Becton, Dickinson and Company) (NYSE:BDX) announced today that it will conduct a live webcast of its third fiscal quarter 2020 earnings conference call on Thursday, August 6, 2020, at 8:00...
-
Jun 16, 2020BD Vacutainer® UltraTouch™ Push Button Blood Collection Set with Preattached Holder enhances offerings that protect healthcare workers from needlestick injury
FRANKLIN LAKES, N.J., June 16, 2020 – BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced today that it obtained the CE mark in Europe for the...
-
Jun 5, 2020New thin-walled guiding sheath minimizes the size of the arteriotomy, which can help to reduce access site complications
FRANKLIN LAKES, N.J. (June 5, 2020) – BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the launch of the Halo One™ Thin-Walled...
-
Jun 1, 2020
BD (Becton, Dickinson and Company) (NYSE:BDX), a leading global medical technology company, announced today that it will present at the following upcoming investor conferences: Goldman Sachs 41st...
-
Jun 1, 2020
FRANKLIN LAKES, N.J. (June 1, 2020) – BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that it has completed the acquisition of Straub...
-
May 26, 2020
BD (Becton, Dickinson and Company) (NYSE:BDX), a leading global medical technology company, announced today that it will present at the Jefferies Virtual Healthcare Conference on Thursday, June 4,...
-
May 21, 2020
BD (Becton, Dickinson and Company) (NYSE:BDX) announced today that it has priced its previously announced registered offerings of $1.5 billion of common stock, par value $1.00 per share, at a...
-
May 19, 2020
BD (Becton, Dickinson and Company) (NYSE:BDX) announced today that it has commenced registered offerings of $1.5 billion of common stock, par value $1.00 per share, and $1.5 billion of depositary...
-
May 7, 2020- As reported, revenues of $4.253 billion increased 1.4 percent
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today reported quarterly revenues of $4.253 billion for the second fiscal quarter ended March 31, 2020....
-
May 5, 2020
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced today that it will present at the Bank of America Securities Virtual Healthcare Conference...
-
Apr 28, 2020
The Board of Directors of BD (Becton, Dickinson and Company) (NYSE: BDX) has declared a quarterly dividend of $0.79 per common share, payable on June 30, 2020 to holders of record on June 9, 2020....
-
Apr 27, 2020Recalls for BodyGuard® Infusion Pumps and Certain Lots of CMEAmerica BodyGuard® Microsets Designated as Class I Recalls
CME America, a wholly owned subsidiary of BD (Becton, Dickinson and Company), a leading global medical technology company, today issued the following update regarding two previously announced...
-
Apr 13, 2020New Test Uses BD MAX™ System to Augment Supply from Existing Collaborations; Test Results in Under Three Hours
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that the U.S. Food and Drug Administration (FDA) has granted Emergency Use...
-
Apr 6, 2020
BD (Becton, Dickinson and Company) (NYSE: BDX) announced today that it will conduct a live webcast of its second fiscal quarter 2020 earnings conference call on Thursday, May 7, 2020, at 8:00 a.m....
-
Apr 3, 2020New Test Immediately Available to Increase Capacity of Rapid, On-Site Testing of COVID-19 at Hospitals Across the U.S.
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, and BioGX Inc., a molecular diagnostics company, today announced that the U.S. Food and Drug...
-
Mar 31, 2020Point-of-care blood test detects evidence of present or past exposure in 15 minutes
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, and BioMedomics, a privately held, North Carolina-based clinical diagnostics company, today announced...
-
Mar 16, 2020New Diagnostics Have Potential to Increase Capacity of COVID-19 Testing in U.S. by Thousands of Tests Per Day
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, and BioGX Inc, a molecular diagnostics company, today announced that the companies have submitted...
-
Mar 13, 2020
BD (Becton, Dickinson and Company) (NYSE: BDX), today issued the following statement after a White House meeting with CEOs of companies who have been involved in the effort to expand access to...
-
Mar 12, 2020
FRANKLIN LAKES, N.J. (March 12, 2019) – BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, issued the following statement: BD no longer manufactures or...
-
Mar 10, 2020CerTest Biotec launches CE Marked COVID-19 diagnostic test for the BD MAX™ System
CerTest Biotec, along with BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that the VIASURE SARS-CoV-2 Real Time PCR Detection Kit...
-
Mar 9, 2020
FRANKLIN LAKES, N.J. (March 9, 2020) – BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today provided an update on a previously announced voluntary...
-
Mar 2, 2020
BD (Becton, Dickinson and Company) (NYSE:BDX), a leading global medical technology company, announced today that it will present at the Barclays Global Healthcare Conference on Wednesday, March...
-
Feb 27, 2020
SANTA BARBARA, Calif., Feb 27, 2020 -- Direct Relief, BD (Becton, Dickinson and Company) and the National Association of Free & Charitable Clinics (NAFC) today announced $125,000 in funding for...
-
Feb 20, 2020
FRANKLIN LAKES, N.J., February 20, 2020 – BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that BD Synapsys™ microbiology...
-
Feb 17, 2020BD Kiestra™ ReadA is device listed with the U.S. FDA
FRANKLIN LAKES, N.J., February 17, 2020 – BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that the BD Kiestra™ ReadA is device...
-
Feb 13, 2020
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced a new, $6 million contract with the Fleming Fund, a U.K. aid program that helps low-...
-
Feb 12, 2020New capillary blood collection device combined with innovative sample handling and analytical technologies in clinical studies aim to make diagnostic blood testing more accessible and convenient
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company and Babson Diagnostics, a transformative diagnostic blood testing company, today announced a long-term...
-
Feb 11, 2020
FRANKLIN LAKES, N.J. (Feb. 11, 2020) – BD (Becton, Dickinson and Company), a leading global medical technology company, today announced the completion of a 50-subject human clinical trial with...
-
Feb 6, 2020- As reported, revenues of $4.225 billion increased 1.6 percent.
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today reported quarterly revenues of $4.225 billion for the first fiscal quarter ended December 31,...
-
Jan 29, 2020Three-year mortality and amputation data for Lutonix® 014 Drug-Coated Balloon Below-The-Knee IDE trial presented at LINC
FRANKLIN LAKES, N.J. (Jan. 29, 2020) – BD (Becton, Dickinson and Company), a leading global medical technology company, today announced that interim findings from the Lutonix below-the-knee...
-
Jan 27, 2020
The Board of Directors of BD (Becton, Dickinson and Company) (NYSE: BDX) has declared a quarterly dividend of $0.79 per common share, payable on March 31, 2020 to holders of record on March 10,...
-
Jan 23, 2020
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced today that it will host a live webcast of its Annual Meeting of Shareholders on Tuesday,...
-
Jan 17, 2020
The meta-analysis published by Dr. Konstantinos Katsanos, et al in the Journal of Vascular and Interventional Radiology on January 14 focused on amputation-free survival (defined as freedom from...
-
Jan 9, 2020
BD (Becton, Dickinson and Company) (NYSE:BDX) announced today that it will conduct a live webcast of its first fiscal quarter 2020 earnings conference call on Thursday, February 6, 2020, at 8:00...
-
Jan 3, 2020
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced today that it will present at the 38th Annual J.P. Morgan Healthcare Conference on Tuesday,...
-
Nov 25, 2019
The Board of Directors of BD (Becton, Dickinson and Company) (NYSE: BDX) has declared a quarterly dividend of $0.79 cents per common share, an increase of 2.6 percent from the previous quarter....
-
Nov 22, 2019
BD (Becton, Dickinson and Company) (NYSE:BDX), a leading global medical technology company, announced today that it will present at the Evercore ISI 2nd Annual HealthCONx Conference on Wednesday,...
-
Nov 21, 2019New antimicrobial stewardship technology will be demonstrated at ASHP 2019 Midyear Meeting
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced its latest advancement in combating antimicrobial resistance (AMR) with new analytics...
-
Nov 18, 2019BD Kiestra™ IdentifA system is available in Europe (CE marked) and Canada
FRANKLIN LAKES, NJ (November 18, 2019) – BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced availability in Europe (CE marked) and...
-
Nov 15, 2019
BD (Becton, Dickinson and Company) (NYSE: BDX) announced today that it has been notified of an unsolicited mini-tender offer by TRC Capital Investment Corporation ("TRC") to purchase up to 500,000...
-
Nov 14, 2019
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced today that it will present at the Jefferies 2019 London Healthcare Conference on Thursday,...
-
Nov 12, 2019
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that it has submitted a pre-market approval (PMA) supplement to the U.S. Food and Drug...
-
Nov 5, 2019- As reported, full fiscal year revenues of $17.290 billion increased 8.2 percent.
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today reported quarterly revenues of $4.584 billion for the fourth fiscal quarter ended September 30,...
-
Oct 29, 2019
FRANKLIN LAKES, N.J., and WAGENINGEN, THE NETHERLANDS, October 29, 2019 – BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, along with Check-Points...
-
Oct 28, 2019BD Rhapsody™ Whole Transcriptome Analysis (WTA) Amplification Kit is designed and tested to work with BD Rhapsody™ Single-Cell Analysis System, BD® AbSeq reagents and BD® Single-Cell Multiplexing Kit
Franklin Lakes, N.J., October 28, 2019 – BD (Becton, Dickinson and Company), a leading global medical technology company, today announced the availability of BD Rhapsody WTA Amplification kit...
-
Oct 3, 2019
BD (Becton, Dickinson and Company) (NYSE:BDX) announced today that it will conduct a live webcast of its fourth fiscal quarter and full fiscal year 2019 earnings conference call on Tuesday,...
-
Sep 28, 2019Independent analysis of LUTONIX® 035 Drug Coated Balloon patient-level data showed no statistically significant mortality increase
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the publication of a company-initiated, independent analysis of the LUTONIX® 035 Drug...
-
Sep 26, 2019Thomas E. Polen Appointed Chief Executive Officer, Effective Jan. 28, 2020
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that Vincent A. Forlenza, chairman and CEO, will retire as CEO on Jan. 28, 2020,...
-
Aug 21, 2019
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced today that it will present at the following upcoming investor healthcare conferences: Wells...
-
Aug 6, 2019- As reported, revenues of $4.350 billion increased 1.7 percent.
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today reported quarterly revenues of $4.350 billion for the third fiscal quarter ended June 30, 2019....
-
Jul 23, 2019
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today issued its 2018 Sustainability Report, focusing on management of the environmental, social and...
-
Jul 22, 2019
The Board of Directors of BD (Becton, Dickinson and Company) (NYSE: BDX) has declared a quarterly dividend of $0.77 per common share, payable on September 30, 2019 to holders of record on...
-
Jul 18, 2019
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today provided an update on two voluntary recalls related to certain Alaris™ Pump Modules Model 8100...
-
Jul 2, 2019
BD (Becton, Dickinson and Company) (NYSE:BDX) announced today that it will conduct a live webcast of its third fiscal quarter 2019 earnings conference call on Tuesday, August 6, 2019, at 8:00 a.m....
-
Jun 20, 2019
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today issued the following statement following the U.S. Food and Drug Administration (FDA) Circulatory...
-
Jun 4, 2019
Becton, Dickinson and Company (NYSE: BDX) (the "Company" or "BD") today announced the consideration payable in connection with its previously announced tender offers to purchase for cash, in the...
-
Jun 4, 2019Findings Based on Survey of 650 Health Care Professionals
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today released a new report based on an independent national survey that examines drug diversion in...
-
Jun 3, 2019
Becton, Dickinson and Company (NYSE: BDX) (the "Company" or "BD") today announced the early tender results for its previously announced tender offers to purchase for cash, in the order of priority...
-
May 31, 2019
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced today that it will present at the Goldman Sachs 40th Annual Global Healthcare Conference on...